M a n u s c r i p t 2 Abstract (250 words) 26
Enterococcus faecium, a major cause of potentially life-threatening hospital-acquired 27 human infections, can be resistant to several antimicrobials, such that streptogramin 28 quinupristin-dalfopristin (Q/D) is one of the few antibiotics still effective. 29
Consequently use of the streptogramin virginiamycin as an animal growth promoter 30 was banned in the EU in 1999 as some believed this contributed to the emergence of 31 Q/D resistant E. faecium. Virginiamycin is advocated for preventing equine pasture-32 associated laminitis, but its effect on equine faecal bacterial Q/D resistance has not 33 been determined. Faecal samples were obtained from horses receiving virginiamycin, 34 horses co-grazing and horses not exposed to virginiamycin. Streptogramin resistant E. 35 faecium were cultured from 70% (21/30) of animals treated with virginiamycin, 75% 36 (18/24) of co-grazing animals and 69% (11/16) of animals not exposed. ermB and 37 vatD genes were detected using real time PCR in 63% and 66% of animals treated 38 with virginiamycin, 75% and 71% of co-grazing animals and 63% and 69% of 39 animals not exposed. Antimicrobial resistance genes were present only in samples 40 which had cultured Q/D resistant E. faecium. There was no significant difference 41 between groups with respect to antimicrobial resistance. The gene load of vatD was 42 significantly (p=0.04) greater in unexposed animals compared to those treated with 43 virginiamycin. The use of virginiamycin to prevent pasture-associated laminitis does 44 not appear to be related to an increased Q/D resistance frequency. However, in view 45 of the high frequency of resistance within all groups, the horse is a reservoir of Q/D 46 resistant genes and clones that potentially could be transferred transiently to humans. Consequently, use of virginiamycin as a growth promoter was banned in the European 66 Union (EU) in 1999 (Soltani et al., 2000) . Thus, as the horse is regarded as a food 67 producing animal by the EU, virginiamycin can only be prescribed for the prevention 68 of pasture-associated laminitis in the United Kingdom (UK) on a named horse using a 69 Special Treatment Certificate from the Veterinary Medicines Directorate. 70
71
The aim of this study was to evaluate the effect of virginiamycin use in horses and 72 ponies for the prevention of pasture-associated laminitis on streptogramin resistance 73 amongst enterococci from equine faecal samples as this has not previously been 74 investigated. 75 M a n u s c r i p t
Materials and Methods 76
Samples 77
Faecal samples were obtained from 30 animals kept at varying geographic locations 78 across the UK which had been treated with oral virginiamycin (Founderguard™) for 79 the prevention of pasture-associated laminitis for at least one month (group 1); from 80 one control animal not receiving virginiamycin but grazing the same pasture as 81 virtually every treated animal (group 2, n=24); and 16 animals kept at a single 82 location which had never been treated with virginiamycin, were grazing pasture which 83 had never knowingly been exposed to virginiamycin and had no contact with group 1 84 or 2 animals (group 3). All the faecal samples were collected individually 85 immediately following defaecation into sterile 50ml universal containers. Aventis, Guilford, UK) using concentrations ranging from 0.5 g/ml to 32 g/ml was 96 M a n u s c r i p t
Real-Time Polymerase Chain Reaction (QPCR) 125
The vatD, ermB and GAPDH PCR products were purified using Wizard SV Gel and 126 PCR Clean-up System (Promega UK Ltd, Southampton, UK) and cloned following 127 the manufacturer's recommendations using pGEM-T Easy Vector System with 128 JM109 High Efficiency Competent Cells (Promega UK Ltd, Southampton, UK). 129
Plasmid DNA from selected clones was extracted using GenElute HP Plasmid 
Statistical Analysis 151
The MIC50, MIC90 and MIC were compared between the 3 groups using a one way 152 ANOVA with Bonferroni's post hoc test. The proportion of samples which contained 153 Q/D resistant E. faecium and E. faecalis was compared between the 3 groups using a 154 chi-squared test. Expression of ermB and vatD were normalised to the expression of 155 GAPDH in the same total bacterial DNA sample, creating a gene expression ratio. 156
The data was tested for normality using a D'Agostino & Pearson omnibus normality 157 test and found to be not normally distributed. Therefore data was compared between 158 the 3 groups of animals using a Kruskall Wallace test. The analysis was performed 159 using commercially available statistical software (GraphPad Prism version 5.0) and 160 p<0.05 was considered statistically significant. 161
162

Results
163
Antimicrobial susceptibility of enterococci 164
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